Graft-versus-host disease (GvHD) is one of the most significant complications of allogeneic stem cell transplantation. Several international guidelines streamline its diagnosis and severity scoring [1] [2] [3] [4] 12] . Their implementation, however, remains challenging due to the variety of presentations of GvHD and the absence of validated biomarkers to confirm diagnosis. Poor GvHD assessment can be also due to sub-optimal knowledge of guidelines, incomplete patient assessment and/or lack of experience, as repeatedly shown through surveys [5] [6] [7] [8] [9] and expert board reviews of clinical trials data [10, 11] . Improving the accuracy of GvHD assessment has thus the potential to enhance the validity of research findings and clinical observations. E-tools can improve data capturing bedside, by offering easy and intuitive access to the latest guidelines, as well as automated help in applying complex decision algorithms. The Complications and Quality of Life Transplant Complications Working Party (CQLWP) of the European Society for Blood and Marrow Transplantation (EBMT) has therefore developed the eGVHD App to serve as a 'pocketGvHD expert' and its preliminary testing in a limited number of healthcare professionals was promising [7] .
Here we aimed at further testing the accuracy and usability of the eGVHD App in a more diverse group of healthcare professionals and to evaluate current practice patterns in GvHD assessment. To do so, we used a 'prepost' single arm design involving a convenience sample of interdisciplinary healthcare professionals participating in the CQLWP eGVHD App session during the EBMT 2017 annual congress in Marseilles, France. This 60-min session provided general information on the eGVHD App's functionalities, followed by an interactive survey on GvHD assessment skills and practice patterns. All participants, who had access to an interactive voting system (IVS) device (TurningPoint) to record their answers and a mobile device (tablet, smartphone, and laptop) to access the App, could participate in the study.
The accuracy of GvHD assessment skills was evaluated using two expert-validated clinical vignettes as the gold standard (case 1: "acute grade II" GvHD according to the Keystone [2] and MAGIC criteria [12] ; case 2: "moderate chronic" GvHD according to the NIH 2014 criteria [3] ). The GvHD severity assessment of each clinical vignette was done twice by all participants: once using self-assessment (relying exclusively on participant's knowledge of the relevant guidelines) and once using the eGVHD App (accessed on their own mobile device by a dedicated weblink). The accuracy of these two methods was calculated by comparing results with the gold standard (i.e., "correct" or "incorrect").
A structured questionnaire was used for capturing participant characteristics (gender, age, professional background, and activity), practice patterns in GvHD assessment -current practice and confidence in using international guidelines for acute (aGvHD) and chronic GvHD (cGvHD) -and feedback on eGVHD App use (actual use, subjective reliability, subjective accuracy, likelihood of use, type of use, type of device, and language issues).
The effect of the eGVHD App on the accuracy of GvHD assessment was analyzed using Mc Nemar's test for proportionality of paired results. To correct for missing results, the statistical analysis was restricted to the participants having answered both the self-assessment and the eGVHD App-assisted GvHD assessment for each clinical vignettes. Sensitivity analyzes were performed, by analyzing separately the results of medical professionals and of professionals scoring GvHD in routine practice. All survey results were reported descriptively.
Eighty-three participants used an IVS device and answered at least one survey question, their characteristics are shown in Table 1 . The most frequently used guidelines were the Glucksberg guidelines for aGvHD and the NIH 2014 guidelines for cGvHD. A minority of participants was 'very' confident in their ability to apply the guidelines. About 30% reported being 'not so' or 'not' confident in their scoring ability.
Forty-four participants evaluated the "grade II" aGvHD clinical vignette both by self-assessment and using the eGVHD App. The number of correct answers increased from 22 (50%) using self-assessment to 39 (89%) when using the App, resulting in an Odds ratio (OR) of 4.4 (95% CI 1.626-14.873; p = 0.002) in favor of using the App (Fig. 1a) . Without the App, participants tended to overestimate the severity of aGvHD: 20 (45%) provided scores that were too high and 2 (5%) provided scores that were too low. In total, 19 (43%) participants improved on their initial assessment after using the App. The aGvHD score remained wrong in 3 participants (7%) and worsened in 2 participants (5%) using the App. The remainder of the participants (n = 20, 45%) did not change their initial correct answer. Similarly, 47 participants evaluated the "moderate" cGvHD clinical vignette both by self-assessment and using the eGVHD App. The number of correct answers for these participants increased from 29 (62%) using self-assessment to 42 (89%) when using the eGVHD App. This resulted in an Odds ratio of 5.8 (95% CI 2.245-14.98; p < 0.0001) in favor of using the App (Fig. 1c) . Before using the App, participants tended to under-estimate the severity of cGvHD: 14 (30%) provided scores that were too low and 4 (9%) provided scores that were too high. In total, 17 (36%) participants improved on their initial assessment after using the App. The cGvHD score remained incorrect in one participant (2%) and worsened in 4 participants (9%) using the App. The remaining participants (n = 25, 53%) gave the same correct answer again. A sensitivity analysis was performed in the following subgroups: medical doctors only (Fig. 1b, d ) and participants reporting scoring GvHD in the practice pattern survey (data not shown). Similar trends were observed, albeit not reaching statistical significance, likely due to the low sample sizes.
Feedback about the use of the eGVHD App is summarized in Table 1 . The majority of the participants effectively tried out the App, and reported good confidence in the tool (79%) and its accuracy (78%). Ninety-four percent reported being likely to use it in their daily practice. A minority expected to use the App bedside only (8%), with the majority expecting to use it either exclusively at their desk (38%) or both bedside and deskside (49%). The majority felt they were able to use the App in English.
This survey reports the current uptake of international GvHD guidelines in a diverse group of hematopoietic cell transplantation professionals and evaluates the potential impact of an e-tool, the eGVHD App, in assessing the severity of GvHD. Participating EBMT healthcare professionals do not use the most recent GvHD guidelines consistently. Indeed, the Glucksberg criteria still seem to be more popular than any of their updated versions, including the most recent MAGIC criteria, and up to one fourth of participants does not report using the most recent NIH 2014 criteria. Although the confidence of participants in their ability to apply the guidelines is reasonable (particularly for No, I did not want to try it out 3 5%
How reliable did you find your GvHD scoring using the eGVHD app? (n = 66) the medical doctors subgroup, data not shown), their application of the guidelines to clinical vignettes suggests limited accuracy of their knowledge-based scoring ability. Accuracy of severity scoring, however, significantly improved when professionals were given the eGVHD App. In addition, usability testing of the eGVHD App was positive, showing good uptake and confidence in the tool. This study has obvious limitations, owing to the limited methodological options to test the first-time use of a new e-tool in a diverse group of professionals during a one-hour session. Due to these contextual constraints, the number of surveyed participants varied over time, suggesting both drop-out and late arrivals during the session. Participants did not systematically answer all questions, thereby limiting the value of the answers collected and precluding extended sub-group analysis. We also realize that the artificial setting of expert-validated clinical vignettes is not strictly comparable to the actual examination of a patient in the clinical setting with all standard scoring forms at hand. Moreover, a learning effect, occurring between the initial GvHD selfassessment answer and the subsequent App-assisted answer, cannot be excluded. Finally, the use of the eGVHD App during the session was assisted by the presenter, which helped users work in a systematic fashion, potentially creating a bias for a better result coming from the Appassisted group.
Despite these limitations, this survey shows a clear need for an unequivocal international agreement on the most up to date guidelines to be used for GvHD assessment. Such an effort is currently being undertaken by experts from the EBMT, the National Institute of Health and the Center for International Blood and Marrow Transplant Research to align healthcare professionals in speaking a 'common language' when referring to GvHD assessment. Second, we were able to show a significant improvement in accuracy of severity scoring when using the eGVHD App compared to self-assessment. Feedback was positive for first-time users, suggesting a potential for successful implementation in daily practice. This survey therefore adds to the emerging evidence [7, [12] [13] [14] [15] ] that e-tools could pave the way to more consistent and uniform evaluation of GvHD, hopefully translating in more reliable outcome evaluation and research results in the near future.
